Oligodendroglioma
Drug research and approvals for oligodendroglioma: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 25 studies of oligodendroglioma are recruiting on ClinicalTrials.gov, Health Canada has authorized 0 drug trials for it since 2013, FDA has 1 approved and 0 open orphan designations naming it, and the EU has 1 authorised medicine for it.
- Recruiting worldwide: 25
- Trials authorized in Canada: 0
- FDA orphan approvals: 1
- EU medicines: 1
- Safety and Efficacy Study of Safusidenib in Participants With IDH1-Mutant Glioma Who Discontinued Vorasidenib Treatment…NCT07703436 · Phase 2 · Nuvation Bio Inc. · starts Mar 1, 2027
- Living Well With Brain Cancer: A Group-Based Intervention to Promote Whole-Person Well-BeingNCT07628647 · Not applicable · University of Colorado, Denver · starts Jun 10, 2026
- Multicenter Prospective Study on MRI AI Model for Midline Glioma Subtyping and Prognosis:NCT07608003 · Not reported · Xiangya Hospital of Central South University · starts May 10, 2026
- Retifanlimab With or Without Difluoromethylornithine for the Treatment of Progressive High Grade GliomasNCT07468136 · Phase 1 / Phase 2 · Mayo Clinic · starts Jun 23, 2026
- Inflammation in Primary and Secondary Malignancies of the Central Nervous System Using [C-11]-CS1P1NCT07462507 · Phase 2 · Washington University School of Medicine · starts Apr 16, 2026
- Pre-Radiation Chemotherapy for Newly Diagnosed High-Grade Glioma.NCT07439172 · Phase 2 · Cooper Norcross Health · starts Jul 13, 2026
- Vorasidenib Study in Pediatric Participants With Grade 2 Astrocytoma or Oligodendroglioma With an IDH1 or IDH2 MutationNCT07286292 · Phase 2 · Institut de Recherches Internationales Servier (I.R.I.S.) · starts Jul 23, 2026
- Amino Acid PET-based Response Assessment in IDH-mutant Gliomas (APPEAR)NCT07159607 · Not reported · LMU Klinikum · starts Jul 17, 2025
- FearLess in NeuroOncologyNCT06989086 · Not applicable · Virginia Commonwealth University · starts Jun 24, 2025
Approved 1
- VorasidenibIDH1/IDH2 inhibitor
Phase 3 2
- TemozolomideDNA inhibitor
- CarmustineGlutathione reductase inhibitor
Phase 2 12 of 29
- BevacizumabVascular endothelial growth factor A inhibitor
- CarboplatinDNA inhibitor
- AfliberceptVascular endothelial growth factor A inhibitor
- Chlorotoxin
- DoxorubicinDNA topoisomerase II alpha inhibitor
- EverolimusFK506-binding protein 1A inhibitor
- IrinotecanDNA topoisomerase I inhibitor
- StreptozocinDNA inhibitor
- SunitinibMacrophage colony stimulating factor receptor inhibitor
- VandetanibTyrosine-protein kinase SRC inhibitor
- MercaptopurineAmidophosphoribosyltransferase inhibitor
- BendamustineDNA inhibitor
Phase 1 or earlier 12 of 29
- Cintredekin besudotoxInterleukin 13 receptor binding agent
- Hiltonol
- TemsirolimusFK506-binding protein 1A inhibitor
- Vocimagene amiretrorepvec
- VorinostatHistone deacetylase 1 inhibitor
- ErlotinibEpidermal growth factor receptor erbB1 inhibitor
- Perifosine
- Etoposide phosphateDNA topoisomerase II alpha inhibitor
- IsotretinoinRetinoic acid receptor agonist
- TopotecanDNA topoisomerase I inhibitor
- FlucytosineThymidylate synthase inhibitor
- SorafenibSerine/threonine-protein kinase RAF inhibitor
How its trials ended
201 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 73 whose ending is known, 19% met their primary endpoint, 14% missed it and 67% stopped early.
- Completed, result not reported8040%
- Ongoing3718%
- Stopped: other or unclear2311%
- Met its primary endpoint147%
- Stopped: enrollment or feasibility115%
- Status unknown115%
- Missed its primary endpoint105%
- Stopped: sponsor or business decision105%
- Stopped: lack of efficacy21%
- Stopped: funding21%
- Stopped: safety1<1%
| Date | Drug | Sponsor | Status |
|---|---|---|---|
| Aug 6, 2024 | VoranigoTreatment of adult and pediatric patients 12 years and older with Grade 2 astrocytoma or oligodendroglioma with a susceptible isocitrate… | Servier Pharmaceuticals LLC | Approved |
| Authorised | Medicine | Holder | EPAR |
|---|---|---|---|
| Sep 17, 2025 | VoranigoVorasidenib · orphan | Les Laboratoires Servier | EMA ↗ |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA